Incyte presented the latest positive 54-week data on its investigational drug Povorcitinib for the treatment of hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

Incyte presented the latest positive 54-week data on its investigational drug Povorcitinib for the treatment of hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

老虎证券2026/03/28 19:32

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

These delayed but important breakthrough research results further validate the long-term efficacy and safety of this therapy, bringing new hope to patients.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Incyte presented the latest positive 54-week data on its investigational drug Povorcitinib for the treatment of hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

You may also like

Crypto prices